The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Lung Cancer Liquid Biopsy-Global Market Insights and Sales Trends 2024
Synopsis
The global Lung Cancer Liquid Biopsy market size is expected to reach US$ 1082 million by 2029, growing at a CAGR of 14.0% from 2023 to 2029. The market is mainly driven by the significant applications of Lung Cancer Liquid Biopsy in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Lung Cancer Liquid Biopsy market. Exosomes and RNA, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTCs and ctDNA segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Lung Cancer Liquid Biopsy market, driven by demand from China, the second largest economy with some signs of stabilising, the Lung Cancer Liquid Biopsy market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Lung Cancer Liquid Biopsy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Lung Cancer Liquid Biopsy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Lung Cancer Liquid Biopsy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Lung Cancer Liquid Biopsy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Lung Cancer Liquid Biopsy covered in this report include RainDanceTechnologies, Biocartis, Qiagen, Guardant Health, MDxHealth, Pathway Genomics, NeoGenomics Laboraories, Sysmex Inostics and Cynvenio, etc.
The global Lung Cancer Liquid Biopsy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
RainDanceTechnologies
Biocartis
Qiagen
Guardant Health
MDxHealth
Pathway Genomics
NeoGenomics Laboraories
Sysmex Inostics
Cynvenio
Menarini Silicon Biosystems
Adaptive Biotechnologies
Biocept
Angle plc
Global Lung Cancer Liquid Biopsy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Lung Cancer Liquid Biopsy market, Segment by Type:
Exosomes and RNA
CTCs and ctDNA
Global Lung Cancer Liquid Biopsy market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Lung Cancer Liquid Biopsy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Lung Cancer Liquid Biopsy market size is expected to reach US$ 1082 million by 2029, growing at a CAGR of 14.0% from 2023 to 2029. The market is mainly driven by the significant applications of Lung Cancer Liquid Biopsy in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Lung Cancer Liquid Biopsy market. Exosomes and RNA, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTCs and ctDNA segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Lung Cancer Liquid Biopsy market, driven by demand from China, the second largest economy with some signs of stabilising, the Lung Cancer Liquid Biopsy market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Lung Cancer Liquid Biopsy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Lung Cancer Liquid Biopsy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Lung Cancer Liquid Biopsy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Lung Cancer Liquid Biopsy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Lung Cancer Liquid Biopsy covered in this report include RainDanceTechnologies, Biocartis, Qiagen, Guardant Health, MDxHealth, Pathway Genomics, NeoGenomics Laboraories, Sysmex Inostics and Cynvenio, etc.
The global Lung Cancer Liquid Biopsy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
RainDanceTechnologies
Biocartis
Qiagen
Guardant Health
MDxHealth
Pathway Genomics
NeoGenomics Laboraories
Sysmex Inostics
Cynvenio
Menarini Silicon Biosystems
Adaptive Biotechnologies
Biocept
Angle plc
Global Lung Cancer Liquid Biopsy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Lung Cancer Liquid Biopsy market, Segment by Type:
Exosomes and RNA
CTCs and ctDNA
Global Lung Cancer Liquid Biopsy market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Lung Cancer Liquid Biopsy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Lung Cancer Liquid Biopsy
1.1 Lung Cancer Liquid Biopsy Market Overview
1.1.1 Lung Cancer Liquid Biopsy Product Scope
1.1.2 Lung Cancer Liquid Biopsy Market Status and Outlook
1.2 Global Lung Cancer Liquid Biopsy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Lung Cancer Liquid Biopsy Market Size by Region (2018-2029)
1.4 Global Lung Cancer Liquid Biopsy Historic Market Size by Region (2018-2023)
1.5 Global Lung Cancer Liquid Biopsy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Lung Cancer Liquid Biopsy Market Size (2018-2029)
1.6.1 North America Lung Cancer Liquid Biopsy Market Size (2018-2029)
1.6.2 Europe Lung Cancer Liquid Biopsy Market Size (2018-2029)
1.6.3 Asia-Pacific Lung Cancer Liquid Biopsy Market Size (2018-2029)
1.6.4 Latin America Lung Cancer Liquid Biopsy Market Size (2018-2029)
1.6.5 Middle East & Africa Lung Cancer Liquid Biopsy Market Size (2018-2029)
2 Lung Cancer Liquid Biopsy Market by Type
2.1 Introduction
2.1.1 Exosomes and RNA
2.1.2 CTCs and ctDNA
2.2 Global Lung Cancer Liquid Biopsy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Lung Cancer Liquid Biopsy Historic Market Size by Type (2018-2023)
2.2.2 Global Lung Cancer Liquid Biopsy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Lung Cancer Liquid Biopsy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Lung Cancer Liquid Biopsy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Lung Cancer Liquid Biopsy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Lung Cancer Liquid Biopsy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Lung Cancer Liquid Biopsy Revenue Breakdown by Type (2018-2029)
3 Lung Cancer Liquid Biopsy Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Lung Cancer Liquid Biopsy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Lung Cancer Liquid Biopsy Historic Market Size by Application (2018-2023)
3.2.2 Global Lung Cancer Liquid Biopsy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Lung Cancer Liquid Biopsy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Lung Cancer Liquid Biopsy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Lung Cancer Liquid Biopsy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Lung Cancer Liquid Biopsy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Lung Cancer Liquid Biopsy Revenue Breakdown by Application (2018-2029)
4 Lung Cancer Liquid Biopsy Competition Analysis by Players
4.1 Global Lung Cancer Liquid Biopsy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Lung Cancer Liquid Biopsy as of 2022)
4.3 Date of Key Players Enter into Lung Cancer Liquid Biopsy Market
4.4 Global Top Players Lung Cancer Liquid Biopsy Headquarters and Area Served
4.5 Key Players Lung Cancer Liquid Biopsy Product Solution and Service
4.6 Competitive Status
4.6.1 Lung Cancer Liquid Biopsy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 RainDanceTechnologies
5.1.1 RainDanceTechnologies Profile
5.1.2 RainDanceTechnologies Main Business
5.1.3 RainDanceTechnologies Lung Cancer Liquid Biopsy Products, Services and Solutions
5.1.4 RainDanceTechnologies Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.1.5 RainDanceTechnologies Recent Developments
5.2 Biocartis
5.2.1 Biocartis Profile
5.2.2 Biocartis Main Business
5.2.3 Biocartis Lung Cancer Liquid Biopsy Products, Services and Solutions
5.2.4 Biocartis Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.2.5 Biocartis Recent Developments
5.3 Qiagen
5.3.1 Qiagen Profile
5.3.2 Qiagen Main Business
5.3.3 Qiagen Lung Cancer Liquid Biopsy Products, Services and Solutions
5.3.4 Qiagen Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.3.5 Guardant Health Recent Developments
5.4 Guardant Health
5.4.1 Guardant Health Profile
5.4.2 Guardant Health Main Business
5.4.3 Guardant Health Lung Cancer Liquid Biopsy Products, Services and Solutions
5.4.4 Guardant Health Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.4.5 Guardant Health Recent Developments
5.5 MDxHealth
5.5.1 MDxHealth Profile
5.5.2 MDxHealth Main Business
5.5.3 MDxHealth Lung Cancer Liquid Biopsy Products, Services and Solutions
5.5.4 MDxHealth Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.5.5 MDxHealth Recent Developments
5.6 Pathway Genomics
5.6.1 Pathway Genomics Profile
5.6.2 Pathway Genomics Main Business
5.6.3 Pathway Genomics Lung Cancer Liquid Biopsy Products, Services and Solutions
5.6.4 Pathway Genomics Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.6.5 Pathway Genomics Recent Developments
5.7 NeoGenomics Laboraories
5.7.1 NeoGenomics Laboraories Profile
5.7.2 NeoGenomics Laboraories Main Business
5.7.3 NeoGenomics Laboraories Lung Cancer Liquid Biopsy Products, Services and Solutions
5.7.4 NeoGenomics Laboraories Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.7.5 NeoGenomics Laboraories Recent Developments
5.8 Sysmex Inostics
5.8.1 Sysmex Inostics Profile
5.8.2 Sysmex Inostics Main Business
5.8.3 Sysmex Inostics Lung Cancer Liquid Biopsy Products, Services and Solutions
5.8.4 Sysmex Inostics Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.8.5 Sysmex Inostics Recent Developments
5.9 Cynvenio
5.9.1 Cynvenio Profile
5.9.2 Cynvenio Main Business
5.9.3 Cynvenio Lung Cancer Liquid Biopsy Products, Services and Solutions
5.9.4 Cynvenio Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.9.5 Cynvenio Recent Developments
5.10 Menarini Silicon Biosystems
5.10.1 Menarini Silicon Biosystems Profile
5.10.2 Menarini Silicon Biosystems Main Business
5.10.3 Menarini Silicon Biosystems Lung Cancer Liquid Biopsy Products, Services and Solutions
5.10.4 Menarini Silicon Biosystems Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.10.5 Menarini Silicon Biosystems Recent Developments
5.11 Adaptive Biotechnologies
5.11.1 Adaptive Biotechnologies Profile
5.11.2 Adaptive Biotechnologies Main Business
5.11.3 Adaptive Biotechnologies Lung Cancer Liquid Biopsy Products, Services and Solutions
5.11.4 Adaptive Biotechnologies Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.11.5 Adaptive Biotechnologies Recent Developments
5.12 Biocept
5.12.1 Biocept Profile
5.12.2 Biocept Main Business
5.12.3 Biocept Lung Cancer Liquid Biopsy Products, Services and Solutions
5.12.4 Biocept Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.12.5 Biocept Recent Developments
5.13 Angle plc
5.13.1 Angle plc Profile
5.13.2 Angle plc Main Business
5.13.3 Angle plc Lung Cancer Liquid Biopsy Products, Services and Solutions
5.13.4 Angle plc Lung Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.13.5 Angle plc Recent Developments
6 North America
6.1 North America Lung Cancer Liquid Biopsy Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Lung Cancer Liquid Biopsy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Liquid Biopsy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Lung Cancer Liquid Biopsy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Liquid Biopsy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Lung Cancer Liquid Biopsy Market Dynamics
11.1 Lung Cancer Liquid Biopsy Industry Trends
11.2 Lung Cancer Liquid Biopsy Market Drivers
11.3 Lung Cancer Liquid Biopsy Market Challenges
11.4 Lung Cancer Liquid Biopsy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
